HAE Speaks podcast

Nina's HAE Treatment Journey

21.10.2026
0:00
37:18
15 Sekunden vorwärts
15 Sekunden vorwärts

This month’s episode of HAE Speaks provides insight into living with hereditary angioedema (HAE) and treatment with TAKHZYRO® (lanadelumab-flyo), a prescription medicine used to prevent attacks of HAE in people two years of age and older. Join Chaeli Wallace, Takeda’s Senior Manager for Patient Community and Education, as she interviews Nina, a person living with HAE, about her journey from diagnosis to treatment with TAKHZYRO. Thank you to Takeda for sponsoring this episode!


What is TAKHZYRO?

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.


IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

  • wheezing

  • difficulty breathing

  • chest tightness

  • fast heartbeat

  • faintness

  • rash

  • hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see full Important Safety Information within the podcast and full Prescribing Information for TAKHZYRO here.


Weitere Episoden von „HAE Speaks“